A standard cross-company combination agreement that takes weeks, not years, to sign
Companies with drugs that might work together rarely test them because the legal negotiation takes longer than the trial. A pre-written standard contract would fix that.
The CRUK Combinations Alliance and NCI CTEP show that a neutral third party with template agreements can run combination studies across companies. Extending this to an industry-wide, pre-negotiated 'combination clinical trial agreement' (like the standard licences in software) covering supply, data, publication, IP on combination findings and a default revenue rule would remove the largest non-scientific barrier.
- Too many combinations to test · There are thousands of possible drug pairs and sequences. Trials can test a few dozen a year.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
Pages like this
not linked directly; found by shared links- IdeaA publicly held library of investigational drugs available for academic combination trials
Shares Secrecy and intellectual property block collaboration, Too many combinations to test, National Cancer Institute (NIH).
- IdeaDisclose R&D and manufacturing costs of publicly funded cancer drugs to get coverage
- IdeaPublish per-patient trial cost benchmarks and target halving them
- IdeaPublicly funded cancer AI must release open weights and model cards
- IdeaLiving plain-language evidence summaries for every common cancer question in 20 languages
- IdeaA regulator-endorsed standard contract for inter-company combination trials
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaGrant progress reports must list what did not work
- IdeaA precompetitive consortium for the twenty hardest cancer targets
Shares Secrecy and intellectual property block collaboration, Cancer Research UK.